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Developing a successful treatment for alopecia areata
(AA), clearly has not been at the forefront of the
agenda for new drug/device development among
the pharmaceutical and medical device industry. The
National Alopecia Areata Foundation (NAAF), a patient
advocacy group, initiated a plan to facilitate and drive
clinical research toward finding safe and efficacious
treatments for AA. As such, Alopecia Areata Uniform
Protocols for clinical trials to test new treatments for
AA were developed. The design of the uniform proto-
col is to accomplish the development of a plug-and-
play template as well as to provide a framework
wherein data from studies utilizing the uniform proto-
col can be compared through consistency of inclu-
sions/exclusions, safety, and outcome assessment
measures. A core uniform protocol for use by pharma-
ceutical companies in testing proof of concept for
investigational products to treat AA. The core protocol
includes standardized title, informed consent, inclu-
sion/exclusion criteria, disease outcome assessments,
and safety assessments. The statistical methodology to
assess successful outcomes will also be standardized.
The protocol as well as the informed consent form has
been approved in concept by Liberty IRB and is ready
to present to pharmaceutical companies.
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INTRODUCTION
Developing a successful treatment for alopecia areata (AA)
clearly has not been at the forefront of the agenda for new
drug/device development among the pharmaceutical and
medical device industry. Currently, no Federal Food and Drug
Administration (FDA) approved therapy exists (Shapiro et al.,
1997; Lachgar et al., 1998; Wiseman et al., 2001; Olsen et al.,
2004; Blume-Peytavi et al., 2011; Gilhar et al., 2012).
The National Alopecia Areata Foundation (NAAF), a patient
advocacy group, initiated a plan to facilitate and drive clinical
research toward finding safe and efficacious treatments for AA.
NAAF, following FDA Guidelines (FDA, 2010), obtained
support in principle from the FDA, to develop Alopecia
Areata Uniform Protocols for clinical trials to test new treat-
ments for AA. The design of the uniform protocol is meant to
accomplish two overall goals: firstly, the uniform protocol is to
be a plug-and-play template to entice biopharmaceutical and
medical device companies to test medications and devices on
AA. Secondly, the AAUP is to be a framework wherein data
from clinical trials for the treatment of AA can be easily
compared through consistency of inclusions/exclusions, safety,
and outcome assessment measures.
RESULTS
A core protocol for a pharmaceutical investigative product
proof of concept was developed and approved by the SAC.
The title accepted is ‘‘Uniform Core Protocol for Phase
(II /III) of A Double-Blind, Vehicle Controlled, Randomized,
Multi-Center Study to Evaluate the Safety and Therapeutic
Efficacy of oENTER IP4 Treatment of Adult Patients with
Moderate to Severe Scalp Alopecia Areata.’’
The calculation of power follows d1:d2: v (Treatment
Dose 1: Treatment Dose 2: Vehicle) For a P-value percentage
difference between treatment Dose 1 (d1), Dose 2 (d2), and
vehicle (veh)-treated subjects on the primary efficacy
end point, treatment d1, d2, and veh-treated subjects will be
required to provide p% power with a two-sided test
at a significance level of 0.05. Screened: d1 þ d2 þ vþs
Enrolled (Randomized): (d1 þ d2 þ vþs) * % Planned
Complete: d1 þ d2 þ v. (Dell et al., 2002).
Primary objective is
The primary objective is to assess the safety and therapeutic
efficacy of a 24-week regimen of administration of investiga-
tional products (IP) with x treatment frequency, in adult
subjects with chronic moderate-to-severe scalp AA.
Secondary objectives include
Assessment of the durability of the response over a 12-week
post-treatment period of observation; the subjects’ perceptions
of their scalp disease with treatment, and upon withdrawal of
treatment, in relationship to baseline; the change from
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baseline of the number and width of terminal hairs in the
target site using digital photography; and IP-specific changes
in the biomarker associated with IP.
Inclusion criteria include
Subjects 418 years of age with a diagnosis of scalp AA and at
least 25% scalp hair loss due to AA, for at least 6 months up to
2 years duration. All subjects taking thyroid medication or
hormonal therapy must be on a stable dose for 6 months and
maintain such throughout the study. Female subjects who are
pregnant or who are nursing or plan pregnancy during the
study period are restricted from participation.
Exclusion criteria include
Less than 25% scalp AA involvement; any co-existent andro-
genetic alopecia; prior treatment with IP; active scalp inflam-
mation; history of systemic or cutaneous medical, or
psychiatric disease which will put patient at risk or interfere
with assessments.
Disease outcome assessments include
Severity of Alopecia Tool (SALT) score (Figure 1); digital
photography; IP-related biomarkers, subject oriented AA
assessments (Figure 2) Skindex, and Mendoza AA Qol Burden
of Disease Questionnaire.
Safety assessments include
Adverse event history, changes in concomitant medications
and/or diseases, physical exam, vital signs, electrocardiogram,
chest X-ray, safety blood and urine labs, and IP-specific safety
labs.
Analysis
The methods of analysis will be calculated according to
standard statistical methods to maintain significance based
on knowledge of the investigative product or device being
tested. A minimal significance of Po0.05 two-tailed will be
maintained. Wherein possible, one should justify the number
of subjects with a preliminary power calculation, as published
by Dell et al. (2002) for calculating sample size, using the
formula n¼1þ 2C(s/d)2, where n¼ number to enroll, C is
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Figure 1. Map of core protocol for pharmaceutical investigative drug. The pharmaceutical company would edit this protocol with input specific to the
investigative drug.
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Figure 2. Severity of Alopecia Tool (SALT) score methodology (Reprinted
from Olsen et al., 2004 with permission from the Journal of the American
Academy of Dermatology).
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constant dependent on desired power and significance, s is
SD, and d is difference to detect.
In summary, the development of the AA core uniform
protocols and their modules hopefully will encourage and
facilitate the testing of new drugs and devices in patients with
AA. Moreover, the uniformity of the process will allow for
comparisons between and among treatments studied. Thus, by
having uniform protocols available for industry, more treat-
ments can be developed and tested with an improved ability
to compare the efficacy of one treatment or another for each
and all of the AA variants.
MATERIALS AND METHODS
Members of the NAAF Scientific Advisory Committee (SAC) provided
historical protocols for a variety of previous AA investigations. The
SAC concurred with an overall plan to develop a uniform protocol
made up of two core uniform protocols for all forms of A one for
pharmaceutical agents, and another for medical devices. Since there
are no currently FDA approved treatments for AA, the initial core
protocols are developed for proof of concept investigations. The core
has a standardized title, power of study, informed consent form (ICF),
inclusion/exclusion criteria set, outcome assessments, and safety
assessments.(Olsen et al., 2004; Blume-Peytavi et al., 2011; Olsen,
2011; Gilhar et al., 2012) In light of variable responses that may occur
between those patients with patchy AA from those with alopecia
totalis (AT) and/or alopecia universalis (AU), subjects with AT (495%
scalp) or AU (495% scalp as well as diffuse non-scalp involvement)
are included, but are evaluated as separate groups from those with
patchy (25–95%) alopecia.
From these core protocols, modules can be developed for specific
variants in mode of application (topical, oral, injected) frequency of
application (twice daily, monthly), pharmacological /immunological
concepts; device modus of administration (laser, non-laser).
A pharmaceutical or device company may then modify these
modules with factors specific to the investigative product or device
(Figure 3).
Corresponding to this core protocol also developed were an ICF,
and source documents. The protocol and ICF were presented to
Liberty IRB, Deland FL and approved in concept.
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Alopecia areata is a condition that may affect you. Please rate how severe the following
symptoms of your alopecia areata have been in the past week. Please select one response from 0
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Your alopecia areata may interfere with your daily functioning. Please rate how the following
items were interfered with by alopecia areata in the past week. Please select one response from 0
(did not interfere) to 10 (interfered completely) for each item.  
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Figure 3. Alopecia Areata Symptom Impact Scale (AASIS).
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